These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1434852)

  • 1. Tissue plasminogen activator for treatment of livedoid vasculitis.
    Klein KL; Pittelkow MR
    Mayo Clin Proc; 1992 Oct; 67(10):923-33. PubMed ID: 1434852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) treated successfully with tissue plasminogen activator.
    Deng A; Gocke CD; Hess J; Heyman M; Paltiel M; Gaspari A
    Arch Dermatol; 2006 Nov; 142(11):1466-9. PubMed ID: 17116837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose danazol in the treatment of livedoid vasculitis.
    Hsiao GH; Chiu HC
    Dermatology; 1997; 194(3):251-5. PubMed ID: 9187843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dramatic response of livedoid vasculitis to tissue plasminogen activator (tPA).
    Johnson DW; Hawley CM; Strutton G; Gibbs HH
    Aust N Z J Med; 1995 Aug; 25(4):370-1. PubMed ID: 8540885
    [No Abstract]   [Full Text] [Related]  

  • 5. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome?
    Acland KM; Darvay A; Wakelin SH; Russell-Jones R
    Br J Dermatol; 1999 Jan; 140(1):131-5. PubMed ID: 10215783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vasculitis and vasculopathy].
    Marković A
    Acta Med Croatica; 2012 Oct; 66 Suppl 1():19-24. PubMed ID: 23193816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Livedoid vasculopathy with underlying subcutaneous necrotizing venulitis in an asymptomatic hepatitis B virus carrier: is livedoid vasculopathy a true nonvasculitic disorder?
    Ishibashi M; Miyamoto J; Nagasaka T; Chen KR
    Am J Dermatopathol; 2009 May; 31(3):293-6. PubMed ID: 19384073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local treatment of venous ulcers with tissue type plasminogen activator containing ointment.
    Zeegelaar JE; Verheijen JH; Kerckhaert JA; Jankowski I; Faber WR
    Vasa; 1997 May; 26(2):81-4. PubMed ID: 9174382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Livedo vasculitis: report of a case].
    Lefebvre P; Motte S; Wautrecht JC; Cornez N; Delplace J; Dereume JP
    J Mal Vasc; 1996; 21(1):50-3. PubMed ID: 8656092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of livedoid vasculitis to respond to tissue plasminogen activator.
    Murrell DF; Jensen J; O'Keefe EJ
    Arch Dermatol; 1995 Feb; 131(2):231-2. PubMed ID: 7857130
    [No Abstract]   [Full Text] [Related]  

  • 11. Livedoid vasculopathy associated with plasminogen activator inhibitor-1 promoter homozygosity (4G/4G) and prothrombin G20210A heterozygosity: response to t-PA therapy.
    Antunes J; Filipe P; André M; Fraga A; Miltenyi G; Marques Gomes M
    Acta Derm Venereol; 2010; 90(1):91-2. PubMed ID: 20107738
    [No Abstract]   [Full Text] [Related]  

  • 12. Endothelial cell activation in cutaneous vasculitis.
    Jurd KM; Stephens CJ; Black MM; Hunt BJ
    Clin Exp Dermatol; 1996 Jan; 21(1):28-32. PubMed ID: 8689765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial tissue-type plasminogen activator expression, unlike that of urokinase, its receptor, and plasminogen activator inhibitor-1, is increased in chronic venous ulcers.
    Weckroth M; Vaheri A; Virolainen S; Saarialho-Kere U; Jahkola T; Sirén V
    Br J Dermatol; 2004 Dec; 151(6):1189-96. PubMed ID: 15606514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Livedoid Vasculopathy Presenting in a Patient With Sickle Cell Disease.
    Reagin H; Marks E; Weis S; Susa J
    Am J Dermatopathol; 2018 Sep; 40(9):682-685. PubMed ID: 29533274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Livedoid vasculopathy and recurrent thrombosis in a patient with lupus: seronegative antiphospholipid syndrome?
    Sopeña B; Pérez-Rodríguez MT; Rivera A; Ortiz-Rey JA; Lamas J; Freire-Dapena MC
    Lupus; 2010 Oct; 19(11):1340-3. PubMed ID: 20659971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Fibrinolysis: How Efficacy and Safety Can Be Improved.
    Gurewich V
    J Am Coll Cardiol; 2016 Nov; 68(19):2099-2106. PubMed ID: 27810050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinolysis abnormalities in systemic lupus erythematosus and their relation to vasculitis.
    Awada H; Barlowatz-Meimon G; Dougados M; Maisonneuve P; Sultan Y; Amor B
    J Lab Clin Med; 1988 Feb; 111(2):229-36. PubMed ID: 3123585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adalimumab in the Treatment of Recalcitrant Livedoid Vasculopathy.
    Bhatt DM; Bhamburkar S; Madke B; Jangid SD; Khan A
    Cureus; 2023 Dec; 15(12):e50053. PubMed ID: 38186477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of livedoid vasculopathy with low-molecular-weight heparin: report of 2 cases.
    Hairston BR; Davis MD; Gibson LE; Drage LA
    Arch Dermatol; 2003 Aug; 139(8):987-90. PubMed ID: 12925383
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.